824 related articles for article (PubMed ID: 34471056)
1. Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
Takemura M; Niki K; Okamoto Y; Matsuda Y; Omae T; Takagi T; Ueda M
Biol Pharm Bull; 2021; 44(9):1286-1293. PubMed ID: 34471056
[TBL] [Abstract][Full Text] [Related]
2. Opioids for cancer pain - an overview of Cochrane reviews.
Wiffen PJ; Wee B; Derry S; Bell RF; Moore RA
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012592. PubMed ID: 28683172
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study.
Takemura M; Niki K; Okamoto Y; Kawamura T; Kohno M; Matsuda Y; Ikeda K
J Pain Symptom Manage; 2024 Jan; 67(1):39-49.e5. PubMed ID: 37757956
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
[TBL] [Abstract][Full Text] [Related]
7. [New Opioid Options in Japan - Methadone, Tapentadol and Hydromorphone].
Takagi Y; Aruga E
Gan To Kagaku Ryoho; 2018 Feb; 45(2):205-211. PubMed ID: 29483406
[TBL] [Abstract][Full Text] [Related]
8. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan.
Sugiyama Y; Kataoka T; Tasaki Y; Kondo Y; Sato N; Naiki T; Sakamoto N; Akechi T; Kimura K
Jpn J Clin Oncol; 2018 Apr; 48(4):362-366. PubMed ID: 29506199
[TBL] [Abstract][Full Text] [Related]
10. Differences in the Analgesic Effect of Opioids on Pain in Cancer Patients With Spinal Metastases.
Takemura M; Niki K; Okamoto Y; Tamura H; Kawamura T; Kohno M; Matsuda Y; Ikeda K
Palliat Med Rep; 2023; 4(1):220-230. PubMed ID: 37637760
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients.
Inoue S; Saito Y; Tsuneto S; Aruga E; Takahashi H; Uemori M
Jpn J Clin Oncol; 2018 Jun; 48(6):542-547. PubMed ID: 29659913
[TBL] [Abstract][Full Text] [Related]
14. [Opioid switch and change of route of administration in cancer patients treated by morphine].
Michenot N; Rostaing S; Baron L; Faure S; Jovenin N; Hubault P; Delorme T; Collin E; Filbet M; Chvetzoff G; Delorme C; Minello C; Magnet M; Ammar D; Krakowski I; Poulain P
Bull Cancer; 2018 Nov; 105(11):1052-1073. PubMed ID: 30274680
[TBL] [Abstract][Full Text] [Related]
15. Opioid Rotation in Cancer Pain Treatment.
Schuster M; Bayer O; Heid F; Laufenberg-Feldmann R
Dtsch Arztebl Int; 2018 Mar; 115(9):135-142. PubMed ID: 29563006
[TBL] [Abstract][Full Text] [Related]
16. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
[TBL] [Abstract][Full Text] [Related]
17. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
18. Patient-Controlled Intravenous Analgesia for Advanced Cancer Patients with Pain: A Retrospective Series Study.
Peng Z; Zhang Y; Guo J; Guo X; Feng Z
Pain Res Manag; 2018; 2018():7323581. PubMed ID: 29849846
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
